Gileads escapes liability in hepatitis C patent fight with Merck
By Andrew Chung
NEW YORK, June 6 (Reuters) - A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.
The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, after finding Merck's patents were valid.
(Reporting by Andrew Chung; Editing by Leslie Adler)
Terms and Privacy Policy